WO2001030974A3 - Molecules targeting cd40 which do not activate cd40-expressing cells - Google Patents

Molecules targeting cd40 which do not activate cd40-expressing cells Download PDF

Info

Publication number
WO2001030974A3
WO2001030974A3 PCT/US2000/041532 US0041532W WO0130974A3 WO 2001030974 A3 WO2001030974 A3 WO 2001030974A3 US 0041532 W US0041532 W US 0041532W WO 0130974 A3 WO0130974 A3 WO 0130974A3
Authority
WO
WIPO (PCT)
Prior art keywords
activate
expressing cells
molecules targeting
molecules
antigen
Prior art date
Application number
PCT/US2000/041532
Other languages
French (fr)
Other versions
WO2001030974A2 (en
Inventor
Nancy Chang
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Priority to AU24711/01A priority Critical patent/AU2471101A/en
Publication of WO2001030974A2 publication Critical patent/WO2001030974A2/en
Publication of WO2001030974A3 publication Critical patent/WO2001030974A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Abstract

Disclosed are molecules which are not antibodies which bind to the CD40 antigen but which do not cause proliferation, differentiation or activation of B lymphocytes or other cells carrying the CD40 antigen and can inhibit CD40 ligand induced activation. These molecules target, bind to or interact with a particular epitope on CD40. They are useful for treating autoimmune, cell-mediated and antibody-mediated diseases.
PCT/US2000/041532 1999-10-25 2000-10-25 Molecules targeting cd40 which do not activate cd40-expressing cells WO2001030974A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24711/01A AU2471101A (en) 1999-10-25 2000-10-25 Molecules targeting cd40 which do not activate cd40-expressing cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16128199P 1999-10-25 1999-10-25
US60/161,281 1999-10-25

Publications (2)

Publication Number Publication Date
WO2001030974A2 WO2001030974A2 (en) 2001-05-03
WO2001030974A3 true WO2001030974A3 (en) 2007-10-18

Family

ID=22580573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/041532 WO2001030974A2 (en) 1999-10-25 2000-10-25 Molecules targeting cd40 which do not activate cd40-expressing cells

Country Status (2)

Country Link
AU (1) AU2471101A (en)
WO (1) WO2001030974A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAJORATH ET AL.: "Identification of residues on CD40 and its ligand which are critical for the receptor-ligand interaction", BIOCHEMISTRY, vol. 34, 1995, pages 1833 - 1844, XP002947138 *

Also Published As

Publication number Publication date
AU2471101A (en) 2001-05-08
WO2001030974A2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
AU6954398A (en) Antagonistic anti-avb3 integrin antibodies
EP1137658A4 (en) METHODS OF MODULATING TUMOR NECROSIS FACTOR $g(a)-INDUCED EXPRESSION OF CELL ADHESION MOLECULES
HK1046635A1 (en) Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO1998025965A3 (en) Peptides and compounds that bind to the thrombopoietin receptor
WO2000037504A3 (en) Human monoclonal antibodies to ctla-4
CA2376596A1 (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
GEP20105118B (en) Anti-vegf antibodies
EP1775307A3 (en) Bispecific antibody effective to treat B-cell lymphoma and cell line
AU8432498A (en) Human-cd28 specific monoclonal antibodies for antigen non-specific activation oft-lymphocytes
WO1994019466A3 (en) A novel family of anti-carcinoembryonic antigen chimeric antibodies
AU2190997A (en) Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
WO2004029207A3 (en) Optimized fc variants and methods for their generation
AU1632297A (en) Treatment of ocular inflammation by blockage of cell adhesion molecules
WO2005010048A3 (en) Rg1 antibodies and uses thereof
AU3027597A (en) Zinc phosphating with integrated subsequent passivation
WO2002032375A8 (en) Uses of monoclonal antibody 8h9
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
WO1995029236A3 (en) Lymphocyte activation antigens and antibodies thereto
WO2000061622A3 (en) Genes associated with diseases of the kidney
EP1818062A3 (en) An anti HSP90 antibody
WO1996027665A3 (en) Neuron-restrictive silencer factor proteins
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
CA2348026A1 (en) Antibodies against semp1, methods for their production and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CN CU CZ GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP